Revvity (RVTY) 10-Q 12 May 23 2023 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Apr. 02, 2023	May 09, 2023
Entity Listings [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Apr. 02, 2023
Document Transition Report	false
Entity File Number	001-5075
Entity Registrant Name	REVVITY, INC
Entity Incorporation, State or Country Code	MA
Entity Tax Identification Number	04-2052042
Entity Address, Address Line One	940 Winter Street,
Entity Address, City or Town	Waltham,
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02451
City Area Code	781
Local Phone Number	663-6900
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		125,441,002
Entity Central Index Key	0000031791
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	false
Current Fiscal Year End Date	--01-01
PKI [Member]
Entity Listings [Line Items]
Trading Symbol	PKI
Trading Symbol	PKI
PKI 21A [Member]
Entity Listings [Line Items]
Trading Symbol	PKI 21A
Trading Symbol	PKI 21A
Common stock, $1 par value per share [Member]
Entity Listings [Line Items]
Title of 12(b) Security	Common stock, $1 par value per share
Title of 12(b) Security	Common stock, $1 par value per share
1.875% Notes due 2026 [Member]
Entity Listings [Line Items]
Title of 12(b) Security	1.875% Notes due 2026
Title of 12(b) Security	1.875% Notes due 2026
NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Listings [Line Items]
Security Exchange Name	NYSE
Security Exchange Name	NYSE

Condensed Consolidated Income S

Condensed Consolidated Income Statements - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Apr. 02, 2023	Apr. 03, 2022
Revenue from Contract with Customer, Excluding Assessed Tax	$ 674,865	$ 963,163
Cost of Goods and Services Sold	293,499	368,423
Selling, general and administrative expenses	248,557	275,260
Research and development expenses	56,690	57,524
Operating income from continuing operations	76,119	261,956
Interest And Other Expense Net	46,679	37,052
Income from continuing operations before income taxes	29,440	224,904
Provision for income taxes	4,595	40,834
Income from continuing operations	24,845	184,070
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	544,630	(7,108)
Net income	$ 569,475	$ 176,962
Basic earnings (loss) per share:
Income (loss) from continuing operations (per share)	$ 0.20	$ 1.46
Gain (loss) on discontinued operations and dispositions (per share)	4.31	(0.06)
Net income (per share)	4.51	1.40
Diluted earnings (loss) per share:
Income (loss) from continuing operations (per share)	0.20	1.45
Gain (loss) on discontinued operations and dispositions (per share)	4.31	(0.06)
Net income (per share)	$ 4.50	$ 1.40
Weighted average shares of common stock outstanding:
Basic (in shares)	126,285	126,137
Diluted (in shares)	126,469	126,635
Cash dividends per common share	$ 0.07	$ 0.07
Product [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 592,280	$ 731,259
Cost of Goods and Services Sold	257,901	307,367
Service [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	82,585	231,904
Cost of Goods and Services Sold	$ 35,598	$ 61,056

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock Amount [Member]	Common Stock Amount [Member] Net Income [Member]	Common Stock Amount [Member] Other comprehensive loss [Member]	Common Stock Amount [Member] Dividends [Member]	Common Stock Amount [Member] Exercise of employee stock options and related income tax benefits [Member]	Common Stock Amount [Member] Purchases of common stock [Member]	Common Stock Amount [Member] Issuance of common stock for long-term incentive program [Member]	Common Stock Amount [Member] Stock compensation [Member]	Capital In Excess of Par Value [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Common stock, Shares, Issued and outstanding		126,241,000
Beginning Balance at Jan. 02, 2022	$ 7,141,245	$ 126,241								$ 2,760,522	$ 4,417,174	$ (162,692)
Net income	176,962										176,962
Other comprehensive income (loss)	(84,027)
Dividends	(8,905)										(8,905)
Exercise of employee stock options and related income tax benefits	1,397	18								1,379
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations	(55,592)	(307)								(55,285)
Issuance of common stock for long-term incentive program	(12,470)	(188)								(12,282)
Stock compensation	2,792	0								2,792	0	0
Ending Balance at Apr. 03, 2022	7,186,342	$ 126,140								2,721,690	4,585,231	(246,719)
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax	$ (84,027)											(84,027)
Common stock, Shares, Issued and outstanding		126,140,000	0	0	0	18,000	(307,000)	188,000	0
Common stock, Shares, Issued and outstanding	126,300,000	126,300,000
Beginning Balance at Jan. 01, 2023	$ 7,382,876	$ 126,300								2,753,055	4,951,018	(447,497)
Net income	569,475										569,475
Other comprehensive income (loss)	143,116
Dividends	(8,841)										(8,841)
Exercise of employee stock options and related income tax benefits	523	9								514
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations	(67,529)	(516)								(67,013)
Issuance of common stock for long-term incentive program	(11,158)	(188)								(10,970)
Stock compensation	3,032	0								3,032	0	0
Ending Balance at Apr. 02, 2023	8,033,810	$ 125,981								$ 2,700,558	$ 5,511,652	(304,381)
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax	$ 143,116											$ 143,116
Common stock, Shares, Issued and outstanding	125,981,000	125,981,000	0	0	0	9,000	(516,000)	188,000	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2023	Apr. 03, 2022
Net income	$ 569,475	$ 176,962
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Foreign currency translation adjustments, net of income taxes, recognized in other comprehensive income	52,008	(84,011)
Foreign currency translation adjustments, net of income taxes, reclassified to earnings	(90,814)	0
Net foreign currency translation adjustments, net of income taxes	142,822	(84,011)
Unrealized gain on securities, net of income taxes	294	(16)
Other comprehensive income (loss)	143,116	(84,027)
Comprehensive income	$ 712,591	$ 92,935

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Apr. 02, 2023	Jan. 01, 2023
Current assets:
Cash and cash equivalents	$ 2,267,183	$ 454,358
Marketable Securities, Current	193,963	0
Accounts receivable, net	586,922	612,780
Inventories	429,423	405,462
Other current assets	318,116	122,254
Disposal Group, Including Discontinued Operation, Assets, Current	0	1,693,704
Total current assets	3,795,607	3,288,558
Property, plant and equipment, net:
Property, plant and equipment, net	491,162	482,950
Operating Lease, Right-of-Use Asset	167,905	188,351
Intangible assets, net	3,294,657	3,377,174
Goodwill	6,505,956	6,481,768
Other assets, net	382,868	311,054
Total assets	14,638,155	14,129,855
Current liabilities:
Current portion of long-term debt	479,423	470,929
Accounts payable	266,884	272,826
Accrued expenses and other current liabilities	817,432	527,863
Current liabilities of discontinued operations	0	272,865
Total current liabilities	1,563,739	1,544,483
Long-term debt	3,880,984	3,923,347
Deferred taxes and long-term liabilities	1,010,230	1,109,181
Operating Lease, Liability, Noncurrent	149,392	169,968
Total liabilities	6,604,345	6,746,979
Commitments and contingencies (see Note 13)
Stockholders' equity:
Preferred stock—$1 par value per share, authorized 1,000,000 shares; none issued or outstanding	0	0
Common stock—$1 par value per share, authorized 300,000,000 shares; issued and outstanding 125,981,000 shares and 126,300,000 shares at April 2, 2023 and January 1, 2023, respectively	125,981	126,300
Capital in excess of par value	2,700,558	2,753,055
Retained earnings	5,511,652	4,951,018
Accumulated other comprehensive loss	(304,381)	(447,497)
Total stockholders’ equity	8,033,810	7,382,876
Total liabilities and stockholders’ equity	$ 14,638,155	$ 14,129,855

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Apr. 02, 2023	Jan. 01, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 1	$ 1
Preferred stock, authorized	1,000,000	1,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$ 1	$ 1
Common stock, authorized	300,000,000	300,000,000
Common stock, issued	125,981,000	126,300,000
Common stock, Shares, Issued and outstanding	125,981,000	126,300,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2023	Apr. 03, 2022
Operating activities:
Net income	$ 569,475	$ 176,962
(Income) loss from discontinued operations, net of income taxes	(544,630)	7,108
Income from continuing operations	24,845	184,070
Adjustments to reconcile net income from continuing operations to net cash provided by continuing operations:
Restructuring and other costs, net	3,096	8,983
Depreciation and amortization	109,008	109,330
Gain (Loss) on Extinguishment of Debt	(3,345)	119
Stock-based compensation	9,893	14,438
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	(1,360)	693
Amortization of deferred debt financing costs and accretion of discounts	1,792	1,781
Change in fair value of financial securities	(2,768)	12,125
Amortization of acquired inventory revaluation	0	16,868
Unrealized foreign exchange loss	(26,095)	0
Changes in operating assets and liabilities which provided (used) cash, excluding effects from companies purchased and divested:
Accounts receivable, net	34,424	77,398
Inventories	(18,520)	(20,943)
Accounts payable	(4,895)	26,739
Increase (Decrease) in Accrued Expenses and Other	(106,591)	(105,480)
Net cash provided by operating activities of continuing operations	71,674	326,121
Net cash used in operating activities of discontinued operations	(8,211)	(42,906)
Net cash provided by operating activities	63,463	283,215
Investing activities:
Capital expenditures	(20,946)	(26,969)
Purchases of Investments	0	(18,000)
Purchases of marketable securities	(193,454)	0
Cash paid for acquisitions, net of cash acquired	(686)	(3,630)
Net cash used in investing activities of continuing operations	(215,086)	(48,599)
Net cash provided by (used in) investing activities of discontinued operations	2,079,588	(7,707)
Net cash provided by (used in) investing activities	1,864,502	(56,306)
Financing activities:
Payments of borrowings	0	220,000
Proceeds from borrowings	0	220,000
Repayments of Term Loan	0	100,000
Repayments of Senior Debt	(49,603)	0
Settlement of cash flow hedges	0	(762)
Net payments on other credit facilities	7,867	(1,064)
Payments for acquisition-related contingent consideration	(1,475)	0
Proceeds from issuance of common stock under stock plans	523	1,397
Purchases of common stock	(61,656)	(55,592)
Dividends paid	(8,841)	(8,837)
Net cash used in financing activities	(113,185)	(164,858)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	(16,969)	(10,636)
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalent	1,797,811	51,415
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents at beginning of period	470,746	619,337
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents at end of period	2,268,557	670,752
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Cash and cash equivalents	2,267,183	654,756
Restricted Cash, Current	1,019	997
Restricted Cash, Noncurrent	355	0
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	2,268,557	670,752
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents	0	14,999
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]
Non-cash consideration in sale of business	$ 261,317	$ 0

Basis of Presentation

Basis of Presentation	3 Months Ended
	Apr. 02, 2023
Accounting Policies [Abstract]
Basis of Accounting [Text Block]	Basis of Presentation The condensed consolidated financial statements included herein have been prepared by Revvity, Inc. (formerly PerkinElmer, Inc.) (the “Company”), in accordance with accounting principles generally accepted in the United States of America (the “U.S.” or the “United States”) and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information in the footnote disclosures of the financial statements has been condensed or omitted where it substantially duplicates information provided in the Company’s latest audited consolidated financial statements, in accordance with the rules and regulations of the SEC. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes included in its Annual Report on Form 10-K for the fiscal year ended January 1, 2023, filed with the SEC (the “2022 Form 10-K”). The balance sheet amounts at January 1, 2023 in this report were derived from the Company’s audited 2022 consolidated financial statements included in the 2022 Form 10-K. The condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods indicated. The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts and classifications of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The results of operations for the three months ended April 2, 2023 and April 3, 2022, respectively, are not necessarily indicative of the results for the entire fiscal year or any future period. In March 2023, the Company completed the previously announced sale of certain assets and the equity interests of certain entities constituting the Company’s Applied, Food and Enterprise Services businesses (the “Business”). The Business is reported for all pe

Revenue (Notes)

Revenue (Notes) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2023	Apr. 03, 2022
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer [Text Block]	Revenue Disaggregation of revenue In the following tables, revenue is disaggregated by primary geographical markets and primary end-markets. Reportable Segments Three Months Ended April 2, 2023 April 3, 2022 Life Sciences Diagnostics Total Life Sciences Diagnostics Total (In thousands) Primary geographical markets Americas $ 163,854 $ 138,174 $ 302,028 $ 159,797 $ 327,936 $ 487,733 Europe 80,285 104,612 184,897 71,585 198,168 269,753 Asia 84,302 103,638 187,940 74,705 130,972 205,677 $ 328,441 $ 346,424 $ 674,865 $ 306,087 $ 657,076 $ 963,163 Primary end-markets Life sciences $ 328,441 $ — $ 328,441 $ 306,087 $ — $ 306,087 Diagnostics — 346,424 346,424 — 657,076 657,076 $ 328,441 $ 346,424 $ 674,865 $ 306,087 $ 657,076 $ 963,163 Major Customer Concentration Revenues from one customer in the Company’s Diagnostics segment represent approximately $112.7 million of the Company’s total revenue for the three months ended April 3, 2022. No single customer comprises more than 10% of net revenues for the three months ended April 2, 2023 .
Revenue from Contract with Customer, Excluding Assessed Tax	$ 674,865	$ 963,163
Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	302,028	487,733
Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	184,897	269,753
Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	187,940	205,677
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	346,424	657,076
Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	328,441	306,087
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	346,424	657,076
Diagnostics [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	138,174	327,936
Diagnostics [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	104,612	198,168
Diagnostics [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	103,638	130,972
Diagnostics [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	346,424	657,076
Diagnostics [Member] | Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0
Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	328,441	306,087
Life Sciences [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	163,854	159,797
Life Sciences [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	80,285	71,585
Life Sciences [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	84,302	74,705
Life Sciences [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0
Life Sciences [Member] | Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 328,441	$ 306,087

Interest and Other Expense (Inc

Interest and Other Expense (Income), Net	3 Months Ended
	Apr. 02, 2023
Other Income and Expenses [Abstract]
Interest and Other Expense (Income), Net	Interest and Other Expense, Net Interest and other expense, net, consisted of the following: Three Months Ended April 2, April 3, (In thousands) Interest income $ (5,272) $ (595) Interest expense 22,738 28,388 Change in fair value of financial securities (2,768) 12,125 Other components of net periodic pension cost (credit) 2,189 (2,555) Foreign exchange losses and other expense (income), net 29,792 (311) Total interest and other expense, net $ 46,679 $ 37,052

Inventories, Net

Inventories, Net	3 Months Ended
	Apr. 02, 2023
Inventory Disclosure [Abstract]
Inventories, Net	Inventories Inventories consisted of the following: April 2, January 1, (In thousands) Raw materials $ 237,077 $ 190,640 Work in progress 73,966 68,206 Finished goods 118,380 146,616 Total inventories $ 429,423 $ 405,462

Debt

Debt	3 Months Ended
	Apr. 02, 2023
Debt Disclosure [Abstract]
Debt	Debt The Company’s debt consisted of the following: April 2, Outstanding Principal Unamortized Debt Discount Unamortized Debt Issuance Costs Net Carrying Amount (In thousands) Long-Term Debt: Senior Unsecured Revolving Credit Facility $ — $ — $ (2,461) $ (2,461) 0.850% Senior Unsecured Notes due in 2024 (“2024 Notes”) 718,879 (242) (2,677) 715,960 €500,000 Principal 1.875% Senior Unsecured Notes due in 2026 (“2026 Notes”) 543,300 (1,810) (1,654) 539,836 1.900% Senior Unsecured Notes due in 2028 (“2028 Notes”) 500,000 (290) (3,494) 496,216 3.3% Senior Unsecured Notes due in 2029 (“2029 Notes”) 850,000 (1,945) (5,385) 842,670 2.55% Senior Unsecured Notes due in March 2031 ("March 2031 Notes") 400,000 (111) (2,910) 396,979 2.250% Senior Unsecured Notes due in September 2031 (“September 2031 Notes”) 500,000 (1,322) (3,900) 494,778 3.625% Senior Unsecured Notes due in 2051 (“2051 Notes”) 400,000 (4) (4,276) 395,720 Other Debt Facilities, non-current 1,286 — — 1,286 Total Long-Term Debt $ 3,913,465 $ (5,724) $ (26,757) $ 3,880,984 Current Portion of Long-term Debt: 0.550% Senior Unsecured Notes due in 2023 (“2023 Notes”) 467,138 (41) (559) 466,538 Other Debt Facilities, current 12,885 — — 12,885 Total Current Portion of Long-Term Debt 480,023 (41) (559) 479,423 Total $ 4,393,488 $ (5,765) $ (27,316) $ 4,360,407 During the first quarter of fiscal year 2023, the Company repurchased $49.6 million in aggregate principal amount of the 2024 Notes in open market transactions. Subsequent to the first quarter of fiscal year 2023, the Company repurchased $0.8 million in aggregate principal amount of the 2024 Notes in open market transactions. During the first quarter of fiscal year 2023, the Company purchased U.S. treasury securities whose proceeds upon maturity are intended to be utilized to repay outstanding debt securities (see Note 12). January 1, Outstanding Principal Unamortized Debt Discount Unamortized Debt Issuance Costs Net Carrying Amount (In thousands) Long-Term Debt: Senior Unsecured Revolving Credit Facility $ — $ — $ (2,641) $ (2,641) 2024 Notes 771,659 (283) (3,136) 768,240 2026 Notes 533,950 (1,902) (1,779) 530,269 2028 Notes 500,000 (301) (3,631) 496,068 2029 Notes 850,000 (2,000) (5,537) 842,463 March 2031 Notes 400,000 (114) (2,978) 396,908 September 2031 Notes 500,000 (1,353) (3,991) 494,656 2051 Notes 400,000 (4) (4,260) 395,736 Other Debt Facilities, non-current 1,648 — — 1,648 Total Long-Term Debt 3,957,257 (5,957) (27,953) 3,923,347 Current Portion of Long-term Debt: 2023 Notes 467,138 (63) (867) 466,208 Other Debt Facilities, current 4,721 — — 4,721 Total Current Portion of Long-Term Debt 471,859 (63) (867) 470,929 Total $ 4,429,116 $ (6,020) $ (28,820) $ 4,394,276

Earnings Per Share

Earnings Per Share	3 Months Ended
	Apr. 02, 2023
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Basic earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding during the period less restricted unvested shares. Diluted earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding plus all potentially dilutive common stock equivalents, primarily shares issuable upon the exercise of stock options using the treasury stock method. The following table reconciles the number of shares utilized in the earnings per share calculations: Three Months Ended April 2, April 3, (In thousands) Number of common shares—basic 126,285 126,137 Effect of dilutive securities: Stock options 151 339 Restricted stock awards 33 159 Number of common shares—diluted 126,469 126,635 Number of potentially dilutive securities excluded from calculation due to antidilutive impact 753 512 Antidilutive securities include outstanding stock options with exercise prices and average unrecognized compensation cost in excess of the average fair market value of common stock for the related period. Antidilutive options were excluded from the calculation of diluted net income per share and could become dilutive in the future.

Industry Segment Information

Industry Segment Information	3 Months Ended
	Apr. 02, 2023
Segment Reporting [Abstract]
Industry Segment Information	Segment InformationThe Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The Company evaluates the performance of its operating segments based on revenue and operating income. Intersegment revenue and transfers are not significant. The accounting policies of the operating segments are the same as those described in Note 1, Nature of Operations and Accounting Policies, to the audited consolidated financial statements in the 2022 Form 10-K. The principal products and services of the Company’s two operating segments are: • Life Sciences . As a result of the sale of the Business, the former Discovery & Analytical Solutions segment will now be referred to as the Life Sciences segment. This segment provides products and services targeted towards the life sciences market. • Diagnostics . Develops diagnostics, tools and applications focused on clinically-oriented customers, especially within the reproductive health, immunodiagnostics and applied genomics markets. The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the activity related to the mark-to-market adjustment on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments. The primary financial measure by which the Company evaluates the performance of its segments is adjusted operating income, which consists of operating income plus amortization of intangible assets, adjustments to operations arising from purchase accounting (primarily adjustments to the fair value of acquired inventory that are subsequently recognized), acquisition and divestiture-related costs, and other costs that are not expected to recur or are of a non-cash nature, including primarily restructuring actions. Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below: Three Months Ended April 2, April 3, (In thousands) Revenues Life Sciences $ 328,441 $ 306,087 Diagnostics 346,630 657,279 Revenue purchase accounting adjustments (206) (203) Total revenues $ 674,865 $ 963,163 Segment Operating Income Life Sciences $ 129,459 $ 110,181 Diagnostics 74,432 300,899 Corporate (14,697) (17,682) Subtotal reportable segments operating income 189,194 393,398 Amortization of intangible assets (91,811) (95,213) Purchase accounting adjustments 914 (18,004) Acquisition and divestiture-related costs (17,951) (8,817) Significant litigation matters and settlements — (425) Significant environmental matters (1,132) — Restructuring and other, net (3,095) (8,983) Operating income from continuing operations 76,119 261,956 Interest and other expense, net (see Note 4) 46,679 37,052 Income from continuing operations before income taxes $ 29,440 $ 224,904

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Apr. 02, 2023
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders’ Equity Comprehensive Income: The components of accumulated other comprehensive loss consisted of the following: April 2, January 1, (In thousands) Foreign currency translation adjustments, net of income taxes $ (303,842) $ (446,664) Unrecognized prior service costs, net of income taxes (798) (798) Unrealized net gains (losses) on marketable securities, net of income taxes 259 (35) Accumulated other comprehensive loss $ (304,381) $ (447,497) Stock Repurchases: On July 22, 2022, the Company’s Board of Directors (the “Board”) authorized the Company to repurchase shares of common stock for an aggregate amount up to $300.0 million under a stock repurchase program (the “Repurchase Program”). During the three months ended April 2, 2023, the Company repurchased 450,238 shares of common stock under the Repurchase Program for an aggregate cost of $57.9 million. Subsequent to the first quarter of fiscal year 2023, the Company repurchased 554,306 shares of common stock under the Repurchase Program at an aggregate cost of $73.3 million. On April 27, 2023, the Repurchase Program was terminated by the Board and the Board authorized the Company to repurchase shares of common stock for an aggregate amount up to $600.0 million under a new stock repurchase program (the “New Repurchase Program”). No shares remain available for repurchase under the Repurchase Program due to its termination. The New Repurchase Program will expire on April 26, 2025 unless terminated earlier by the Board and may be suspended or discontinued at any time. In addition, the Board has authorized the Company to repurchase shares of common stock to satisfy minimum statutory tax withholding obligations in connection with the vesting of restricted stock awards and restricted stock unit awards granted pursuant to the Company’s equity incentive plans and to satisfy obligations related to the exercise of stock options made pursuant to the Company’s equity incentive plans. During the three months ended April 2, 2023, the Company repurchased 65,993 shares of common stock for this purpose at an aggregate cost of $9.0 million. The repurchased shares have been reflected as additional authorized but unissued shares, with the payments reflected in common stock and capital in excess of par value. Dividends: The Board declared a regular qua rterly cash dividend of $0.07 per share for the first quarter of fiscal year 2023 and in each quarter of fiscal year 2022. At April 2, 2023, the Company had accrued $8.8 million for dividends declared on January 26, 2023 for the first quarter of fiscal year 2023 that will be paid in May 2023. O n April 25, 2023, t he Company announced that the Board had declared a quarterly div idend of $0.07 p er share for the second quarter of fiscal year 2023 that will be payable in August 2023. In the future, the Board may determine to reduce or eliminate the Company’s common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, Net	3 Months Ended
	Apr. 02, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net	Goodwill and Intangible Assets, Net The Company tests goodwill and indefinite-lived intangible assets at least annually for possible impairment. The Company completes the annual testing of impairment for goodwill and indefinite-lived intangible assets on the later of January 1 or the first day of each fiscal year. In addition to its annual test, the Company regularly evaluates whether events or circumstances have occurred that may indicate a potential impairment of goodwill or indefinite-lived intangible assets. The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. If the carrying value of the reporting unit exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of goodwill. The Company performed its annual impairment testing for its reporting units as of January 2, 2023, its annual impairment testing date for fiscal year 2023. There were no impairments measured in the periods presented. While the Company believes that its estimates of current value are reasonable, if actual results differ from the estimates and judgments used, including such items as future cash flows and the volatility inherent in markets which the Company serves, impairment charges against the carrying value of those assets could be required in the future. The changes in the carrying amount of goodwill for the three months ended April 2, 2023 were as follows: Life Sciences Diagnostics Consolidated (In thousands) Balance at January 1, 2023 $ 4,551,575 $ 1,930,193 $ 6,481,768 Foreign currency translation 16,986 7,202 24,188 Balance at April 2, 2023 $ 4,568,561 $ 1,937,395 $ 6,505,956 Identifiable intangible asset balances by category were as follows: April 2, January 1, (In thousands) Patents $ 27,808 $ 28,020 Less: Accumulated amortization (25,900) (26,055) Net patents 1,908 1,965 Trade names and trademarks 151,312 149,453 Less: Accumulated amortization (67,960) (63,590) Net trade names and trademarks 83,352 85,863 Licenses 26,306 62,614 Less: Accumulated amortization (15,069) (54,254) Net licenses 11,237 8,360 Core technology 1,568,659 1,556,740 Less: Accumulated amortization (495,973) (449,689) Net core technology 1,072,686 1,107,051 Customer relationships 2,951,226 2,943,761 Less: Accumulated amortization (831,112) (775,104) Net customer relationships 2,120,114 2,168,657 In-process research and development 5,360 5,278 Total $ 3,294,657 $ 3,377,174

Derivatives And Hedging Activit

Derivatives And Hedging Activities	3 Months Ended
	Apr. 02, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Hedging Activities	Derivatives and Hedging Activities The Company uses derivative instruments as part of its risk management strategy only, and includes derivatives utilized as economic hedges that are not designated as hedging instruments. By nature, all financial instruments involve market and credit risks. The Company enters into derivative instruments with major investment grade financial institutions and has policies to monitor the credit risk of those counterparties. The Company does not enter into derivative contracts for trading or other speculative purposes, nor does the Company use leveraged financial instruments. Appro ximately 50% of the Company’s business is conducted outside of the United States, generally in foreign currencies. As a result, fluctuations in foreign currency exchange rates can increase the costs of financing, investing and operating the business. In the ordinary course of business, the Company enters into foreign exchange contracts for periods consistent with its committed exposures to mitigate the effect of foreign currency movements on transactions denominated in foreign currencies. The intent of these economic hedges is to offset gains and losses that occur on the underlying exposures from these currencies, with gains and losses resulting from the forward currency contracts that hedge these exposures. Transactions covered by hedge contracts include intercompany and third-party receivables and payables. The contracts are primarily in European and Asian currencies, have maturities that do not exceed 12 months, have no cash requirements until maturity, and are recorded at fair value on the Company’s condensed consolidated balance sheets. The unrealized gains and losses on the Company’s foreign currency contracts are recognized immediately in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from operating activities within the Company’s condensed consolidated statement of cash flows. Principal hedged currencies include the Chinese Renminbi, British Pound, Euro and Singapore Dollar. The Company held forward foreign exchange contracts, designated as economic hedges, with U.S. dollar equivalent notional amounts totaling $291.4 million, $476.9 million and $376.6 million at April 2, 2023, January 1, 2023 and April 3, 2022, respectively, and the fair value of these foreign currency derivative contracts was insignificant. The gains and losses realized on these foreign currency derivative contracts are not material. The duration of these contracts was generally 30 days or less during each of the three months ended April 2, 2023 and April 3, 2022. In addition, in connection with certain intercompany loan agreements utilized to finance its acquisitions and stock repurchase program, the Company enters into forward foreign exchange contracts intended to hedge movements in foreign exchange rates prior to settlement of such intercompany loans denominated in foreign currencies. The Company records these hedges at fair value on the Company’s condensed consolidated balance sheets. The unrealized gains and losses on these hedges, as well as the gains and losses associated with the remeasurement of the intercompany loans, are recognized immediately in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from financing activities within the Company’s condensed consolidated statement of cash flows. During fiscal year 2018, the Company designated a portion of the 2026 Notes to hedge its net investments in certain foreign subsidiaries. Unrealized translation adjustments from a portion of the 2026 Notes were included in the foreign currency translation component of accumulated other comprehensive income (“AOCI”), which offsets translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold. As of April 2, 2023, the total notional amount of the 2026 Notes that was designated to hedge net investments in foreign subsidiaries was €497.2 million. The unrealized foreign exchange losses (gains) recorded in AOCI related to the net investment hedge were $9.3 million and $(16.7) million for the three months ended April 2, 2023 and April 3, 2022, respectively. The Company does not expect any material net pre-tax gains or losses to be reclassified from accumulated other comprehensive loss into interest and other expense, net within the next twelve months.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Apr. 02, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents, derivatives, marketable securities and accounts receivable. The Company believes it had no significant concentrations of credit risk as of April 2, 2023. The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during the three months ended April 2, 2023. The Company’s financial assets and liabilities carried at fair value are primarily comprised of marketable securities, derivative contracts used to hedge the Company’s currency risk, and acquisition and divestiture related contingent consideration. The Company has not elected to measure any additional financial instruments or other items at fair value. Valuation Hierarchy: The following summarizes the three levels of inputs required to measure fair value. For Level 1 inputs, the Company utilizes quoted market prices as these instruments have active markets. For Level 2 inputs, the Company utilizes quoted market prices in markets that are not active, broker or dealer quotations, or utilizes alternative pricing sources with reasonable levels of price transparency. For Level 3 inputs, the Company utilizes unobservable inputs based on the best information available, including estimates by management primarily based on information provided by third-party fund managers, independent brokerage firms and insurance companies. A financial asset’s or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of April 2, 2023 and January 1, 2023 classified in one of the three classifications described above: Fair Value Measurements at April 2, 2023 Using: Total Carrying Value at April 2, 2023 Quoted Prices in Significant Other Significant (In thousands) Marketable securities - equity securities $ 13,504 $ 13,504 $ — $ — Marketable securities - U.S. treasury securities 193,963 193,963 — — Foreign exchange derivative assets 332 — 332 — Foreign exchange derivative liabilities (794) — (794) — Contingent consideration assets 15,930 — — 15,930 Contingent consideration liabilities (43,834) — — (43,834) Fair Value Measurements at January 1, 2023 Using: Total Carrying Value at January 1, 2023 Quoted Prices in Significant Other Significant (In thousands) Marketable securities $ 11,083 $ 11,083 $ — $ — Foreign exchange derivative assets 2,142 — 2,142 — Foreign exchange derivative liabilities (1,549) — (1,549) — Contingent consideration liabilities (46,618) — — (46,618) Level 1 and Level 2 Valuation Techniques: The Company’s Level 1 and Level 2 assets and liabilities are comprised of investments in equity, fixed-income and U.S. treasury securities as well as derivative contracts. For financial assets and liabilities that utilize Level 1 and Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including common stock price quotes, foreign exchange forward prices and bank price quotes. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities. Marketable securities - equity securities: Include equity and fixed-income securities measured at fair value using the quoted market prices in active markets at the reporting date. Marketable securities - U.S. treasury securities : Include investments in U.S. treasury securities that are classified as held-to-maturity and measured at fair value using the quoted market prices at the reporting date. Investments amounting to $99.2 million had a contractual maturity of less than one year as of April 2, 2023. Investments amounting to $94.8 million had a contractual maturity of more than one year and less than 2 years as of April 2, 2023. Foreign exchange derivative assets and liabilities: Include foreign exchange derivative contracts that are valued using quoted forward foreign exchange prices at the reporting date. The Company’s foreign exchange derivative contracts are subject to master netting arrangements that allow the Company and its counterparties to net settle amounts owed to each other. Derivative assets and liabilities that can be net settled under these arrangements have been presented in the Company’s condensed consolidated balance sheet on a net basis and are recorded in other assets. As of both April 2, 2023 and January 1, 2023, none of the master netting arrangements involved collateral. Level 3 Valuation Techniques: The Company’s Level 3 assets and liabilities are comprised of contingent consideration related to the sale of the Business (see note 4) and acquisitions. For assets and liabilities that utilize Level 3 inputs, the Company uses significant unobservable inputs. Below is a summary of valuation techniques for Level 3 assets and liabilities. Contingent consideration: Contingent consideration is measured at fair value at the disposition or acquisition date using projected milestone dates, discount rates, volatility, probabilities of success and projected achievement of financial targets, including revenues of the acquired business in many instances. Projected risk-adjusted contingent payments are discounted back to the current period using a discounted cash flow model. The fair value of the contingent consideration asset was initially measured using a lattice model and recognized upon the sale of the Business on March 13, 2023. In accordance with the terms of the sale of the Business, the Company is entitled to receive up to $150.0 million that is contingent on the exit valuation the Sponsor and its affiliated funds receive on a sale or other capital event related to the Business. Potential valuation adjustments may be made as additional information and market factors that impact the expected exit valuation of the Business becomes available, with the impact of such adjustments being recorded in the Company’s condensed consolidated statements of operations. A reconciliation of the contingent consideration assets is as follows: Three Months Ended April 2, (In thousands) Balance at beginning of period $ — Amount recognized upon the sale of the Business 15,930 Change in fair value — Balance at end of period $ 15,930 The fair values of contingent consideration liabilities are calculated on a quarterly basis based on a collaborative effort of the Company’s operations, finance and accounting groups, as appropriate. Potential valuation adjustments are made as additional information becomes available, including the progress towards achieving the revenue targets, with the impact of such adjustments being recorded in the Company’s condensed consolidated statements of operations. A reconciliation of the contingent consideration liabilities is as follows: Three Months Ended April 2, April 3, (In thousands) Balance at beginning of period $ (46,618) $ (57,996) Additions — (4,961) Amounts paid and foreign currency translation 1,424 1,422 Adjustments recognized in goodwill — 12,400 Change in fair value (included within selling, general and administrative expenses) 1,360 (693) Balance at end of period $ (43,834) $ (49,828) Financial Instruments Not Recorded at Fair Value The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturities of these assets and liabilities. If measured at fair value, cash and cash equivalents would be classified as Level 1. The Company’s outstanding senior unsecured notes had a fair value of $3,859.4 million and a carrying value of $4,348.7 million as of April 2, 2023. The Company’s outstanding senior unsecured notes had a fair value of $3,812.3 million and a carrying value of $4,390.5 million as of January 1, 2023. The fair values of the outstanding senior unsecured notes were estimated using market quotes from brokers and were based on current rates offered for similar debt, which are Level 2 measurements. The Company’s other debt facilities had an aggregate carrying value of $11.7 million and $3.7 million as of April 2, 2023 and January 1, 2023, respectively. The carrying value approximates fair value and were classified as Level 2.

Contingencies

Contingencies	3 Months Ended
	Apr. 02, 2023
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies The Company is conducting a number of environmental investigations and remedial actions at current and former locations of the Company and, along with other companies, has been named a potentially responsible party (“PRP”) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Company’s responsibility is established and when the cost can be reasonably estimated. The Company has accrued $13.5 million and $12.2 million as of April 2, 2023 and January 1, 2023, respectively, which represents its management’s estimate of the cost of the remediation of known environmental matters and does not include any potential liability for related personal injury or property damage claims. These amounts were included in accrued expenses and other current liabilities. The Company’s environmental accrual is not discounted and does not reflect the recovery of any material amounts through insurance or indemnification arrangements. The cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the time period over which remediation may occur, and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other significant named parties to contribute. The Company expects that the majority of such accrued amounts could be paid out over a period of up to ten years. As assessment and remediation activities progress at each individual site, these liabilities are reviewed and adjusted to reflect additional information as it becomes available. There have been no environmental problems to date that have had, or are expected to have, a material adverse effect on the Company’s condensed consolidated financial statements. While it is possible that a loss exceeding the amounts recorded in the condensed consolidated financial statements may be incurred, the potential exposure is not expected to be materially different from those amounts recorded. The Company is subject to various claims, legal proceedings, regulatory matters, and investigations covering a wide range of matters that arise in the ordinary course of its business activities. Although the Company has established accruals for potential losses that it believes are probable and reasonably estimable, in the opinion of the Company’s management, based on its review of the information available at this time, the total cost of resolving these contingencies at April 2, 2023 would not have a material adverse effect on the Company’s consolidated financial statements. However, each of these matters is subject to uncertainties, and it is possible that some of these matters may be resolved unfavorably to the Company.

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Apr. 02, 2023
Disaggregation of Revenue [Line Items]
Disaggregation of Revenue [Table Text Block]	In the following tables, revenue is disaggregated by primary geographical markets and primary end-markets. Reportable Segments Three Months Ended April 2, 2023 April 3, 2022 Life Sciences Diagnostics Total Life Sciences Diagnostics Total (In thousands) Primary geographical markets Americas $ 163,854 $ 138,174 $ 302,028 $ 159,797 $ 327,936 $ 487,733 Europe 80,285 104,612 184,897 71,585 198,168 269,753 Asia 84,302 103,638 187,940 74,705 130,972 205,677 $ 328,441 $ 346,424 $ 674,865 $ 306,087 $ 657,076 $ 963,163 Primary end-markets Life sciences $ 328,441 $ — $ 328,441 $ 306,087 $ — $ 306,087 Diagnostics — 346,424 346,424 — 657,076 657,076 $ 328,441 $ 346,424 $ 674,865 $ 306,087 $ 657,076 $ 963,163

Discontinued Operations (Tables

Discontinued Operations (Tables)	3 Months Ended
	Apr. 02, 2023
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	Three Months Ended April 2, April 3, (In thousands) Revenue $ 175,423 $ 296,279 Cost of revenue 124,647 211,788 Selling, general and administrative expenses 74,794 72,528 Research and development expenses 10,434 19,085 Operating loss (34,452) (7,122) Other income (expense): Gain on sale 866,919 — Other income (expense), net 913 (182) Total other income (expense) 867,832 (182) Income (loss) from discontinued operations before income taxes 833,380 (7,304) Provision for (benefit from) income tax 288,750 (196) Income (loss) from discontinued operations $ 544,630 $ (7,108) The table below provides a reconciliation of the carrying amounts of the major classes of assets and liabilities of the discontinued operations to the amounts presented separately in the consolidated balance sheets at April 2, 2023 and January 1, 2023. April 2, January 1, (In thousands) Cash and cash equivalents $ — $ 14,999 Accounts receivable — 343,064 Inventories — 210,367 Other current assets — 32,063 Total current assets 600,493 Property, plant and equipment, net — 60,983 Operating lease right-of-use assets — 41,487 Intangible assets, net — 202,850 Goodwill — 772,812 Other assets, net — 15,079 Total long-term assets 1,093,211 Total assets of discontinued operations $ — $ 1,693,704 Accounts payable $ — $ 29,912 Accrued expenses and other current liabilities — 161,260 Total current liabilities 191,172 Deferred taxes and long-term liabilities — 46,046 Operating lease liabilities — 35,647 Total long-term liabilities 81,693 Total liabilities of discontinued operations $ — $ 272,865 The following operating and investing non-cash items from discontinued operations were as follows for the three months ended: April 2, April 3, (In thousands) Capital expenditures $ 1,292 $ 2,462 Depreciation — 3,285 Amortization — 7,437

Interest and Other Expense (I_2

Interest and Other Expense (Income), Net (Tables)	3 Months Ended
	Apr. 02, 2023
Other Income and Expenses [Abstract]
Interest and Other Expense (Income), Net	Interest and other expense, net, consisted of the following: Three Months Ended April 2, April 3, (In thousands) Interest income $ (5,272) $ (595) Interest expense 22,738 28,388 Change in fair value of financial securities (2,768) 12,125 Other components of net periodic pension cost (credit) 2,189 (2,555) Foreign exchange losses and other expense (income), net 29,792 (311) Total interest and other expense, net $ 46,679 $ 37,052

Inventories, Net (Tables)

Inventories, Net (Tables)	3 Months Ended
	Apr. 02, 2023
Inventory Disclosure [Abstract]
Schedule of Net Inventories	Inventories consisted of the following: April 2, January 1, (In thousands) Raw materials $ 237,077 $ 190,640 Work in progress 73,966 68,206 Finished goods 118,380 146,616 Total inventories $ 429,423 $ 405,462

Debt (Tables)

Debt (Tables)	3 Months Ended
	Apr. 02, 2023
Debt Disclosure [Abstract]
Schedule of Debt	The Company’s debt consisted of the following: April 2, Outstanding Principal Unamortized Debt Discount Unamortized Debt Issuance Costs Net Carrying Amount (In thousands) Long-Term Debt: Senior Unsecured Revolving Credit Facility $ — $ — $ (2,461) $ (2,461) 0.850% Senior Unsecured Notes due in 2024 (“2024 Notes”) 718,879 (242) (2,677) 715,960 €500,000 Principal 1.875% Senior Unsecured Notes due in 2026 (“2026 Notes”) 543,300 (1,810) (1,654) 539,836 1.900% Senior Unsecured Notes due in 2028 (“2028 Notes”) 500,000 (290) (3,494) 496,216 3.3% Senior Unsecured Notes due in 2029 (“2029 Notes”) 850,000 (1,945) (5,385) 842,670 2.55% Senior Unsecured Notes due in March 2031 ("March 2031 Notes") 400,000 (111) (2,910) 396,979 2.250% Senior Unsecured Notes due in September 2031 (“September 2031 Notes”) 500,000 (1,322) (3,900) 494,778 3.625% Senior Unsecured Notes due in 2051 (“2051 Notes”) 400,000 (4) (4,276) 395,720 Other Debt Facilities, non-current 1,286 — — 1,286 Total Long-Term Debt $ 3,913,465 $ (5,724) $ (26,757) $ 3,880,984 Current Portion of Long-term Debt: 0.550% Senior Unsecured Notes due in 2023 (“2023 Notes”) 467,138 (41) (559) 466,538 Other Debt Facilities, current 12,885 — — 12,885 Total Current Portion of Long-Term Debt 480,023 (41) (559) 479,423 Total $ 4,393,488 $ (5,765) $ (27,316) $ 4,360,407 During the first quarter of fiscal year 2023, the Company repurchased $49.6 million in aggregate principal amount of the 2024 Notes in open market transactions. Subsequent to the first quarter of fiscal year 2023, the Company repurchased $0.8 million in aggregate principal amount of the 2024 Notes in open market transactions. During the first quarter of fiscal year 2023, the Company purchased U.S. treasury securities whose proceeds upon maturity are intended to be utilized to repay outstanding debt securities (see Note 12). January 1, Outstanding Principal Unamortized Debt Discount Unamortized Debt Issuance Costs Net Carrying Amount (In thousands) Long-Term Debt: Senior Unsecured Revolving Credit Facility $ — $ — $ (2,641) $ (2,641) 2024 Notes 771,659 (283) (3,136) 768,240 2026 Notes 533,950 (1,902) (1,779) 530,269 2028 Notes 500,000 (301) (3,631) 496,068 2029 Notes 850,000 (2,000) (5,537) 842,463 March 2031 Notes 400,000 (114) (2,978) 396,908 September 2031 Notes 500,000 (1,353) (3,991) 494,656 2051 Notes 400,000 (4) (4,260) 395,736 Other Debt Facilities, non-current 1,648 — — 1,648 Total Long-Term Debt 3,957,257 (5,957) (27,953) 3,923,347 Current Portion of Long-term Debt: 2023 Notes 467,138 (63) (867) 466,208 Other Debt Facilities, current 4,721 — — 4,721 Total Current Portion of Long-Term Debt 471,859 (63) (867) 470,929 Total $ 4,429,116 $ (6,020) $ (28,820) $ 4,394,276

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Apr. 02, 2023
Earnings Per Share [Abstract]
Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations	The following table reconciles the number of shares utilized in the earnings per share calculations: Three Months Ended April 2, April 3, (In thousands) Number of common shares—basic 126,285 126,137 Effect of dilutive securities: Stock options 151 339 Restricted stock awards 33 159 Number of common shares—diluted 126,469 126,635 Number of potentially dilutive securities excluded from calculation due to antidilutive impact 753 512

Industry Segment Information (T

Industry Segment Information (Tables)	3 Months Ended
	Apr. 02, 2023
Segment Reporting [Abstract]
Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations	Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below: Three Months Ended April 2, April 3, (In thousands) Revenues Life Sciences $ 328,441 $ 306,087 Diagnostics 346,630 657,279 Revenue purchase accounting adjustments (206) (203) Total revenues $ 674,865 $ 963,163 Segment Operating Income Life Sciences $ 129,459 $ 110,181 Diagnostics 74,432 300,899 Corporate (14,697) (17,682) Subtotal reportable segments operating income 189,194 393,398 Amortization of intangible assets (91,811) (95,213) Purchase accounting adjustments 914 (18,004) Acquisition and divestiture-related costs (17,951) (8,817) Significant litigation matters and settlements — (425) Significant environmental matters (1,132) — Restructuring and other, net (3,095) (8,983) Operating income from continuing operations 76,119 261,956 Interest and other expense, net (see Note 4) 46,679 37,052 Income from continuing operations before income taxes $ 29,440 $ 224,904

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Apr. 02, 2023
Stockholders' Equity Note [Abstract]
Components of Accumulated Other Comprehensive Loss	The components of accumulated other comprehensive loss consisted of the following: April 2, January 1, (In thousands) Foreign currency translation adjustments, net of income taxes $ (303,842) $ (446,664) Unrecognized prior service costs, net of income taxes (798) (798) Unrealized net gains (losses) on marketable securities, net of income taxes 259 (35) Accumulated other comprehensive loss $ (304,381) $ (447,497)

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets, Net (Tables)	3 Months Ended
	Apr. 02, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in the Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for the three months ended April 2, 2023 were as follows: Life Sciences Diagnostics Consolidated (In thousands) Balance at January 1, 2023 $ 4,551,575 $ 1,930,193 $ 6,481,768 Foreign currency translation 16,986 7,202 24,188 Balance at April 2, 2023 $ 4,568,561 $ 1,937,395 $ 6,505,956
Identifiable Intangible Asset Balances	Identifiable intangible asset balances by category were as follows: April 2, January 1, (In thousands) Patents $ 27,808 $ 28,020 Less: Accumulated amortization (25,900) (26,055) Net patents 1,908 1,965 Trade names and trademarks 151,312 149,453 Less: Accumulated amortization (67,960) (63,590) Net trade names and trademarks 83,352 85,863 Licenses 26,306 62,614 Less: Accumulated amortization (15,069) (54,254) Net licenses 11,237 8,360 Core technology 1,568,659 1,556,740 Less: Accumulated amortization (495,973) (449,689) Net core technology 1,072,686 1,107,051 Customer relationships 2,951,226 2,943,761 Less: Accumulated amortization (831,112) (775,104) Net customer relationships 2,120,114 2,168,657 In-process research and development 5,360 5,278 Total $ 3,294,657 $ 3,377,174

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Apr. 02, 2023
Fair Value Disclosures [Abstract]
Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis	The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of April 2, 2023 and January 1, 2023 classified in one of the three classifications described above: Fair Value Measurements at April 2, 2023 Using: Total Carrying Value at April 2, 2023 Quoted Prices in Significant Other Significant (In thousands) Marketable securities - equity securities $ 13,504 $ 13,504 $ — $ — Marketable securities - U.S. treasury securities 193,963 193,963 — — Foreign exchange derivative assets 332 — 332 — Foreign exchange derivative liabilities (794) — (794) — Contingent consideration assets 15,930 — — 15,930 Contingent consideration liabilities (43,834) — — (43,834) Fair Value Measurements at January 1, 2023 Using: Total Carrying Value at January 1, 2023 Quoted Prices in Significant Other Significant (In thousands) Marketable securities $ 11,083 $ 11,083 $ — $ — Foreign exchange derivative assets 2,142 — 2,142 — Foreign exchange derivative liabilities (1,549) — (1,549) — Contingent consideration liabilities (46,618) — — (46,618)
Reconciliation of Beginning and Ending Level 3 Net Assets	A reconciliation of the contingent consideration assets is as follows: Three Months Ended April 2, (In thousands) Balance at beginning of period $ — Amount recognized upon the sale of the Business 15,930 Change in fair value — Balance at end of period $ 15,930

Disposition of Businesses and A

Disposition of Businesses and Assets, Net (Tables)	3 Months Ended
	Apr. 02, 2023
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	Three Months Ended April 2, April 3, (In thousands) Revenue $ 175,423 $ 296,279 Cost of revenue 124,647 211,788 Selling, general and administrative expenses 74,794 72,528 Research and development expenses 10,434 19,085 Operating loss (34,452) (7,122) Other income (expense): Gain on sale 866,919 — Other income (expense), net 913 (182) Total other income (expense) 867,832 (182) Income (loss) from discontinued operations before income taxes 833,380 (7,304) Provision for (benefit from) income tax 288,750 (196) Income (loss) from discontinued operations $ 544,630 $ (7,108) The table below provides a reconciliation of the carrying amounts of the major classes of assets and liabilities of the discontinued operations to the amounts presented separately in the consolidated balance sheets at April 2, 2023 and January 1, 2023. April 2, January 1, (In thousands) Cash and cash equivalents $ — $ 14,999 Accounts receivable — 343,064 Inventories — 210,367 Other current assets — 32,063 Total current assets 600,493 Property, plant and equipment, net — 60,983 Operating lease right-of-use assets — 41,487 Intangible assets, net — 202,850 Goodwill — 772,812 Other assets, net — 15,079 Total long-term assets 1,093,211 Total assets of discontinued operations $ — $ 1,693,704 Accounts payable $ — $ 29,912 Accrued expenses and other current liabilities — 161,260 Total current liabilities 191,172 Deferred taxes and long-term liabilities — 46,046 Operating lease liabilities — 35,647 Total long-term liabilities 81,693 Total liabilities of discontinued operations $ — $ 272,865 The following operating and investing non-cash items from discontinued operations were as follows for the three months ended: April 2, April 3, (In thousands) Capital expenditures $ 1,292 $ 2,462 Depreciation — 3,285 Amortization — 7,437

Basis of Presentation (Basis of

Basis of Presentation (Basis of Presentation) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2023	Apr. 03, 2022	Jan. 01, 2023
Basis of Presentation [Line Items]
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ (16,969)	$ (10,636)
Operating Lease, Right-of-Use Asset	$ 167,905		$ 188,351

Revenue (Details)

Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2023	Apr. 03, 2022	Jan. 01, 2023
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 674,865	$ 963,163
Contract with Customer, Liability, Current	(21,971)		$ (30,133)
Contract with Customer, Asset, Net, Current	60,808		56,631
Contract with Customer, Asset and Liability [Abstract]
Contract with Customer, Asset, Net, Current	60,808		56,631
Contract with Customer, Liability, Current	(21,971)		$ (30,133)
Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	302,028	487,733
Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	184,897	269,753
Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	187,940	205,677
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	346,424	657,076
Diagnostics [Member] | Customer Concentration Risk [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		112,700
Diagnostics [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	138,174	327,936
Diagnostics [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	104,612	198,168
Diagnostics [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	103,638	130,972
Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	328,441	306,087
Life Sciences [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	163,854	159,797
Life Sciences [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	80,285	71,585
Life Sciences [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	84,302	74,705
Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	328,441	306,087
Life Sciences [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0
Life Sciences [Member] | Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	328,441	306,087
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	346,424	657,076
Diagnostics [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	346,424	657,076
Diagnostics [Member] | Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 0	$ 0

Business Combinations (Narrativ

Business Combinations (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2023	Apr. 03, 2022	Jan. 01, 2023	Jan. 02, 2022
Business Acquisition [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 43,834	$ 49,828	$ 46,618	$ 57,996
Goodwill	6,505,956		6,481,768
Interest Expense	22,738	$ 28,388
Diagnostics [Member]
Business Acquisition [Line Items]
Goodwill	$ 1,937,395		$ 1,930,193

Business Combinations (Fair Val

Business Combinations (Fair Values of the Business Combinations and Allocations for the Acquisitions Completed) (Details) - USD ($) $ in Thousands	Apr. 02, 2023	Jan. 01, 2023
Business Acquisition [Line Items]
Goodwill	$ 6,505,956	$ 6,481,768
Diagnostics [Member]
Business Acquisition [Line Items]
Goodwill	$ 1,937,395	$ 1,930,193

Discontinued Operations (Narrat

Discontinued Operations (Narrative) (Details) - USD ($)	3 Months Ended
	Apr. 02, 2023	Apr. 03, 2022	Mar. 13, 2023	Jan. 01, 2023	Aug. 01, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	$ 544,630,000	$ (7,108,000)
Disposal Group, Including Discontinued Operation, Assets, Current	0			$ 1,693,704,000
Current liabilities of discontinued operations	0			272,865,000
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents	0	14,999,000
Analytical, Food and Enterprise Services businesses [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Consideration					$ 2,450,000,000
Disposal Group, Including Discontinued Operation, Revenue	175,423,000	296,279,000
Disposal Group, Including Discontinued Operation, Accounts Receivable, Net	0			343,064,000
Pre-tax gain on disposal of business unit	866,900,000	0
Discontinued Operation, Tax Effect of Discontinued Operation	288,750,000	(196,000)
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent	544,630,000	(7,108,000)
Disposal Group, Including Discontinued Operation, Inventory, Current	0			210,367,000
Disposal Group, Including Discontinued Operation, Other Assets, Current	0			32,063,000
Disposal Group, Including Discontinued Operation, Assets, Current				600,493,000
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent	0			60,983,000
Disposal Group, Including Discontinued Operation, Operating lease right-of-use assets, Noncurrent	0			41,487,000
Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent	0			202,850,000
Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent	0			772,812,000
Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent	0			15,079,000
Long-term assets of discontinued operations				1,093,211,000
Disposal Group, Including Discontinued Operation, Assets	0			1,693,704,000
Disposal Group, Including Discontinued Operation, Accounts Payable	0			29,912,000
Disposal Group, Including Discontinued Operation, Accrued expenses and other current liabilities	0			161,260,000
Current liabilities of discontinued operations				191,172,000
Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities	0			46,046,000
Disposal Group, Including Discontinued Operation, Operating lease liabilities, Noncurrent	0			35,647,000
Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent				81,693,000
Disposal Group, Including Discontinued Operation, Liabilities	0			272,865,000
Disposal Group, Including Discontinued Operation, Costs of Goods Sold	124,647,000	211,788,000
Disposal Group, Including Discontinued Operation, General and Administrative Expense	74,794,000	72,528,000
Disposal Group, Including Discontinued Operations, Research and development expenses	10,434,000	19,085,000
Disposal Group, Including Discontinued Operation, Operating Income (Loss)	(34,452,000)	(7,122,000)
Disposal Group, Including Discontinued Operation, Total Other Income (Expense)	867,832,000	(182,000)
Discontinued Operation, Income from Discontinued Operation, before Income Tax	833,380,000	(7,304,000)
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation	299,600,000
Disposal Group, Consideration, Receivable at Closing, Deferred Payments Tied to Transfer of the PKI Brand and Related Trademarks			$ 75,000,000
Disposal Group, Consideration, Receivable at Closing, Deferred Payments Tied to Transfer of the PKI Brand and Related Trademarks, Recognized at Closing			68,000,000
Disposal Group, Consideration, Contingent on Exit Valuation			150,000,000
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents	0			$ 14,999,000
Depreciation Exp, Discontinued Operations	0	3,285,000
Amortization, Discontinued Operations	0	7,437,000
Capital Expenditure, Discontinued Operations	1,292,000	2,462,000
Disposal Group, Including Discontinued Operation, Other expense (income), net	$ 913,000	$ (182,000)
Disposal Group, including Discontinued Operations, Receivable at Closing, Working Capital Adjustments			177,500,000
Disposal Group, including Discontinued Operations, Fair Value of Consideration, Contingent on Exit Valuation			15,900,000
Disposal Group, Consideration, Cash Proceeds at Closing			$ 2,140,000,000

Interest and Other Expense (I_3

Interest and Other Expense (Income), Net (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2023	Apr. 03, 2022
Other Income and Expenses [Abstract]
Interest income	$ (5,272)	$ (595)
Interest expense	22,738	28,388
Gain (Loss) on Extinguishment of Debt	3,345	(119)
Change in fair value of financial securities	(2,768)	12,125
Other components of net periodic pension (credit) cost	2,189	(2,555)
Foreign exchange losses and other expense (income), net	29,792	(311)
Total interest and other expense, net	46,679	37,052
Foreign Exchange Losses Related to Proceed from Sale of Business	$ 26,095	$ 0

Inventories, Net (Details)

Inventories, Net (Details) - USD ($) $ in Thousands	Apr. 02, 2023	Jan. 01, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 237,077	$ 190,640
Work in progress	73,966	68,206
Finished goods	118,380	146,616
Total inventories, net	$ 429,423	$ 405,462

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2023	Apr. 03, 2022
Income Tax Contingency [Line Items]
Provision for income taxes	$ 4,595	$ 40,834

Debt (Details)

Debt (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2023	Apr. 03, 2022	Jul. 02, 2023	Jan. 01, 2023
Debt Instrument, Unamortized Discount	$ (5,765)			$ (6,020)
Unamortized Debt Issuance Expense	(27,316)			(28,820)
Current Portion of Long-Term Debt, Gross	480,023			471,859
Debt, Long-term and Short-term, Combined Amount	4,393,488			4,429,116
Long-term Debt, Gross	3,913,465			3,957,257
Repayments of Term Loan	0	$ (100,000)
Current portion of long-term debt	479,423			470,929
Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt	(3,880,984)			(3,923,347)
Debt, Long-term and Short-term, Combined Amount	4,360,407			4,394,276
2.55 Percent Senior Unsecured Notes due in 2031 [Member]
Debt Instrument, Unamortized Discount	(111)			(114)
Unamortized Debt Issuance Expense	(2,910)			(2,978)
Long-term Debt, Gross	400,000			400,000
2.55 Percent Senior Unsecured Notes due in 2031 [Member] | Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt	(396,979)			(396,908)
3.625 Percent Senior Unsecured Notes due in 2051 [Member]
Debt Instrument, Unamortized Discount	(4)			(4)
Unamortized Debt Issuance Expense	(4,276)			(4,260)
Long-term Debt, Gross	400,000			400,000
3.625 Percent Senior Unsecured Notes due in 2051 [Member] | Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt	(395,720)			(395,736)
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]
Debt Instrument, Unamortized Discount	(1,945)			(2,000)
Unamortized Debt Issuance Expense	(5,385)			(5,537)
Long-term Debt, Gross	850,000			850,000
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member] | Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt	(842,670)			(842,463)
Line of Credit, Maturing September 17, 2024 [Member]
Debt Instrument, Unamortized Discount				0
Long-term Debt				(2,641)
Unamortized Debt Issuance Expense				(2,641)
Revolving credit facility outstanding balance				0
1.875 Percent Ten Year Senior Unsecured Notes [Member]
Debt Instrument, Unamortized Discount	(1,810)			(1,902)
Unamortized Debt Issuance Expense	(1,654)			(1,779)
Long-term Debt, Gross	543,300			533,950
1.875 Percent Ten Year Senior Unsecured Notes [Member] | Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt	(539,836)			(530,269)
Other Debt Facilities - Current [Member]
Debt Instrument, Unamortized Discount	0			0
Other Long-term Debt, Current	12,885			4,721
Unamortized Debt Issuance Expense	0			0
Other Debt Facilities - Current [Member] | Significant Other Observable Inputs (Level 2) [Member]
Other Long-term Debt, Current	12,885			4,721
Other Debt Facilities - Non-current [Member]
Debt Instrument, Unamortized Discount	0			0
Other Long-term Debt, Noncurrent	1,286			1,648
Unamortized Debt Issuance Expense	0			0
Other Debt Facilities - Non-current [Member] | Significant Other Observable Inputs (Level 2) [Member]
Other Long-term Debt, Noncurrent	1,286			1,648
Line of Credit, Maturing August 24, 2026 [Member]
Debt Instrument, Unamortized Discount	0
Long-term Debt	(2,461)
Unamortized Debt Issuance Expense	(2,461)
Revolving credit facility outstanding balance	0
0.550% Senior Unsecured Notes due 2023 [Member]
Debt Instrument, Unamortized Discount	(41)			(63)
Unamortized Debt Issuance Expense	(559)			(867)
Current portion of long-term debt	467,138			467,138
0.550% Senior Unsecured Notes due 2023 [Member] | Significant Other Observable Inputs (Level 2) [Member]
Current portion of long-term debt	466,538			466,208
0.850% Senior Unsecured Notes due 2024 [Member]
Debt Instrument, Unamortized Discount	(242)			(283)
Unamortized Debt Issuance Expense	(2,677)			(3,136)
Long-term Debt, Gross	718,879			771,659
Debt Instrument, Repurchase Amount	49,600
0.850% Senior Unsecured Notes due 2024 [Member] | Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt	(715,960)			(768,240)
1.900% Senior Unsecured Notes due 2028 [Member]
Debt Instrument, Unamortized Discount	(290)			(301)
Unamortized Debt Issuance Expense	(3,494)			(3,631)
Long-term Debt, Gross	500,000			500,000
1.900% Senior Unsecured Notes due 2028 [Member] | Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt	(496,216)			(496,068)
2.250% Senior Unsecured Notes due in 2031 [Member]
Debt Instrument, Unamortized Discount	(1,322)			(1,353)
Unamortized Debt Issuance Expense	(3,900)			(3,991)
Long-term Debt, Gross	500,000			500,000
2.250% Senior Unsecured Notes due in 2031 [Member] | Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt	(494,778)			(494,656)
Long-term Debt [Member]
Debt Instrument, Unamortized Discount	(5,724)			(5,957)
Unamortized Debt Issuance Expense	(26,757)			(27,953)
Long-term Debt - Current Portion [Member]
Debt Instrument, Unamortized Discount	(41)			(63)
Unamortized Debt Issuance Expense	$ (559)			$ (867)
Subsequent Event [Member] | 0.850% Senior Unsecured Notes due 2024 [Member]
Debt Instrument, Repurchase Amount			$ 800

Earnings Per Share (Schedule of

Earnings Per Share (Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations) (Details) - shares shares in Thousands	3 Months Ended
	Apr. 02, 2023	Apr. 03, 2022
Earnings Per Share [Abstract]
Number of common shares-basic	126,285	126,137
Effect of dilutive securities, Stock options	151	339
Effect of dilutive securities, Restricted stock	33	159
Number of common shares-diluted	126,469	126,635
Number of potentially dilutive securities excluded from calculation due to antidilutive impact	753	512

Industry Segment Information In

Industry Segment Information Industry Segment Information Narrative (Details)	3 Months Ended
	Apr. 02, 2023 segments
Segment Reporting Information [Line Items]
Number of Operating Segment	2

Industry Segment Information (S

Industry Segment Information (Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2023	Apr. 03, 2022
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 674,865	$ 963,163
Operating income (loss) from continuing operations	76,119	261,956
Interest and other expense, net	46,679	37,052
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	29,440	224,904
Total amortization expense related to finite-lived intangible assets	91,800	95,200
Product [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	592,280	731,259
Service [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	82,585	231,904
Corporate [Member]
Segment Reporting Information [Line Items]
Reportable segment operating income (loss)	(14,697)	(17,682)
Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	346,424	657,076
Reportable segment operating income (loss)	74,432	300,899
Life Sciences [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	328,441	306,087
Reportable segment operating income (loss)	129,459	110,181
Reportable Segment Revenue [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	674,865	963,163
Reportable Segment Revenue [Member] | Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	346,630	657,279
Reportable Segment Revenue [Member] | Life Sciences [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	328,441	306,087
Segment Operating Income [Member]
Segment Reporting Information [Line Items]
Reportable segment operating income (loss)	189,194	393,398
Total amortization expense related to finite-lived intangible assets	(91,811)	(95,213)
Purchase accounting adjustments	914	(18,004)
Business Combination, Acquisition Related Costs	(17,951)	(8,817)
Significant litigation matters and settlements	0	(425)
Significant environmental matters	(1,132)	0
Restructuring and contract termination charges, net	(3,095)	(8,983)
Revenue Purchase Accounting Adjustments [Member] | Reportable Segment Revenue [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ (206)	$ (203)

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Jul. 02, 2023	Apr. 02, 2023	Jan. 01, 2023	Oct. 02, 2022	Jul. 03, 2022	Apr. 03, 2022	Apr. 27, 2023	Jul. 22, 2022
Schedule of Shareholders' Equity [Line Items]
Repurchased Common Shares For Activity Pursuant to Equity Incentive Plans		65,993
Aggregate Cost of Repurchased Common Shares for Activity Pursuant to Equity Incentive Plans		$ 9
Cash dividends (per share)		$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07
Dividends Payable, Amount		$ 8.8
Dividends Payable, Date Declared		Jan. 26, 2023
Repurchase Program, 07/22/2022 [Member]
Schedule of Shareholders' Equity [Line Items]
Stock Repurchase Program, Authorized Amount								$ 300
Number of common stock repurchased in open market		450,238
Aggregate Cost of Repurchased Common Shares Under Repurchase Program		$ 57.9
Subsequent Event [Member]
Schedule of Shareholders' Equity [Line Items]
Cash dividends (per share)	$ 0.07
Subsequent Event [Member] | Repurchase Program, 07/22/2022 [Member]
Schedule of Shareholders' Equity [Line Items]
Number of common stock repurchased in open market	554,306
Aggregate Cost of Repurchased Common Shares Under Repurchase Program	$ 73.3
Subsequent Event [Member] | Repurchase Program, 04/27/2025 [Member]
Schedule of Shareholders' Equity [Line Items]
Stock Repurchase Program, Authorized Amount							$ 600

Stockholders' Equity (Component

Stockholders' Equity (Components Of Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Thousands	Apr. 02, 2023	Jan. 01, 2023
Stockholders' Equity Note [Abstract]
Foreign currency translation adjustments, net of income taxes	$ (303,842)	$ (446,664)
Unrecognized losses and prior service costs, net of income taxes	(798)	(798)
Unrealized net losses on securities, net of income taxes	259	(35)
Accumulated other comprehensive loss	$ (304,381)	$ (447,497)

Stock Plans (Narrative) (Detail

Stock Plans (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2023	Apr. 03, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of common stock under stock plans	$ 523	$ 1,397

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets, Net (Narrative) (Details) - USD ($) $ in Thousands		3 Months Ended
	Jan. 02, 2023	Apr. 02, 2023	Apr. 03, 2022	Jan. 01, 2023
Goodwill and Intangible Assets Net [Line Items]
Goodwill		$ 6,505,956		$ 6,481,768
Total amortization expense related to finite-lived intangible assets		91,800	$ 95,200
Future Amortization Expense, Remainder of Fiscal Year		273,400
Future Amortization Expense, Year One		357,600
Future Amortization Expense, Year Two		336,200
Future Amortization Expense, Year Three		329,000
Future Amortization Expense, Year Four		301,400
Finite-Lived Intangible Assets, Net		3,294,657		3,377,174
Intangible assets, net		3,294,657		3,377,174
Impairment Testing Date	January 2, 2023
Patents [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		27,808		28,020
Less: Accumulated amortization		25,900		26,055
Finite-Lived Intangible Assets, Net		1,908		1,965
Trade Names And Trademarks [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		151,312		149,453
Less: Accumulated amortization		67,960		63,590
Finite-Lived Intangible Assets, Net		83,352		85,863
Licensing Agreements [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		26,306		62,614
Less: Accumulated amortization		15,069		54,254
Finite-Lived Intangible Assets, Net		11,237		8,360
Core Technology [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		1,568,659		1,556,740
Less: Accumulated amortization		495,973		449,689
Finite-Lived Intangible Assets, Net		1,072,686		1,107,051
Customer Relationships [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		2,951,226		2,943,761
Less: Accumulated amortization		831,112		775,104
Finite-Lived Intangible Assets, Net		2,120,114		2,168,657
In-process Research and Development [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		$ 5,360		$ 5,278

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets, Net (Changes in the Carrying Amount of Goodwill) (Details) $ in Thousands	3 Months Ended
	Apr. 02, 2023 USD ($)
Changes in the carrying amount of goodwill
Balance at beginning of period	$ 6,481,768
Foreign currency translation	24,188
Balance at end of period	6,505,956
Diagnostics [Member]
Changes in the carrying amount of goodwill
Balance at beginning of period	1,930,193
Foreign currency translation	7,202
Balance at end of period	1,937,395
Life Sciences [Member]
Changes in the carrying amount of goodwill
Balance at beginning of period	4,551,575
Foreign currency translation	16,986
Balance at end of period	$ 4,568,561

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets, Net (Identifiable Intangible Asset Balances) (Details) - USD ($) $ in Thousands	Apr. 02, 2023	Jan. 01, 2023
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Net amortizable intangible assets	$ 3,294,657	$ 3,377,174
Intangible assets, net	3,294,657	3,377,174
Patents [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	27,808	28,020
Less: Accumulated amortization	(25,900)	(26,055)
Net amortizable intangible assets	1,908	1,965
Trade Names And Trademarks [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	151,312	149,453
Less: Accumulated amortization	(67,960)	(63,590)
Net amortizable intangible assets	83,352	85,863
Licensing Agreements [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	26,306	62,614
Less: Accumulated amortization	(15,069)	(54,254)
Net amortizable intangible assets	11,237	8,360
Core Technology [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	1,568,659	1,556,740
Less: Accumulated amortization	(495,973)	(449,689)
Net amortizable intangible assets	1,072,686	1,107,051
Customer Relationships [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	2,951,226	2,943,761
Less: Accumulated amortization	(831,112)	(775,104)
Net amortizable intangible assets	2,120,114	2,168,657
In-process Research and Development [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	$ 5,360	$ 5,278

Derivatives And Hedging Activ_2

Derivatives And Hedging Activities (Details) $ in Thousands, € in Millions	3 Months Ended
	Apr. 02, 2023 USD ($)	Apr. 02, 2023 EUR (€)	Apr. 03, 2022 USD ($)	Jan. 01, 2023 USD ($)
Derivative [Line Items]
Company's business conducted outside United States	50%	50%
Payments for (Proceeds from) Hedge, Financing Activities	$ 0		$ 762
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net	$ 0
European And Asian Currencies [Member]
Derivative [Line Items]
Maximum maturity period for foreign exchange contracts, in months	12 months	12 months
Duration Of Foreign Currency Derivatives	30 days	30 days
Fair Value Hedging [Member]
Derivative [Line Items]
Derivative, Notional Amount	$ 291,400		376,600	$ 476,900
Net Investment Hedging [Member] | 1.875 Percent Ten Year Senior Unsecured Notes [Member]
Derivative [Line Items]
Unrealized Gain (Loss) on Net Investment Hedge in AOCI	$ (9,300)		$ 16,700
Euro Member Countries, Euro | Net Investment Hedging [Member] | 1.875 Percent Ten Year Senior Unsecured Notes [Member]
Derivative [Line Items]
Notional Amount of Nonderivative Instruments | €		€ 497.2

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) $ in Thousands, € in Millions	3 Months Ended
	Apr. 02, 2023 USD ($)	Apr. 03, 2022 USD ($)	Apr. 02, 2023 EUR (€)	Mar. 13, 2023 USD ($)	Jan. 01, 2023 USD ($)	Jan. 01, 2023 EUR (€)	Jan. 02, 2022 USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 43,834	$ 49,828			$ 46,618		$ 57,996
Unamortized Debt Issuance Expense	27,316				28,820
Debt Instrument, Unamortized Discount	(5,765)				(6,020)
Payments for acquisition related contingent consideration	(1,475)	$ 0
Analytical, Food and Enterprise Services businesses [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Disposal Group, Consideration, Contingent on Exit Valuation				$ 150,000
2.55 Percent Senior Unsecured Notes due in 2031 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unamortized Debt Issuance Expense	2,910				2,978
Debt Instrument, Unamortized Discount	(111)				(114)
3.625 Percent Senior Unsecured Notes due in 2051 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unamortized Debt Issuance Expense	4,276				4,260
Debt Instrument, Unamortized Discount	(4)				(4)
Line of Credit, Maturing September 17, 2024 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Revolving credit facility outstanding balance					0
Unamortized Debt Issuance Expense					2,641
Long-term Debt					2,641
Debt Instrument, Unamortized Discount					0
1.875 Percent Ten Year Senior Unsecured Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unamortized Debt Issuance Expense	1,654				1,779
Debt Instrument, Unamortized Discount	(1,810)				(1,902)
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unamortized Debt Issuance Expense	5,385				5,537
Debt Instrument, Unamortized Discount	(1,945)				(2,000)
Senior Unsecured Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unsecured senior notes, fair value	$ 3,859,400				3,812,300
DNA Labs & Biosense [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Description	Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash.
Quoted Prices In Active Markets (Level 1) [Member] | Fair Value, Recurring [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 0				0
Investments in US Treasury Securities maturing in less than 1 year	99,200
Investments in US Treasury Securities maturing in 1-2 years	94,800
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt	3,880,984				3,923,347
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Recurring [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	0				0
Significant Other Observable Inputs (Level 2) [Member] | 2.55 Percent Senior Unsecured Notes due in 2031 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt	396,979				396,908
Significant Other Observable Inputs (Level 2) [Member] | 3.625 Percent Senior Unsecured Notes due in 2051 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt	395,720				395,736
Significant Other Observable Inputs (Level 2) [Member] | 1.875 Percent Ten Year Senior Unsecured Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt	539,836				530,269
Significant Other Observable Inputs (Level 2) [Member] | 3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt	842,670				842,463
Significant Other Observable Inputs (Level 2) [Member] | Senior Unsecured Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt	4,348,700				4,390,500
Significant Other Observable Inputs (Level 2) [Member] | Other Debt Facilities, including the senior revolving credit facility [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other Long-term Debt | €			€ 11.7			€ 3.7
Significant Unobservable Inputs (Level 3) [Member] | Fair Value, Recurring [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 43,834				$ 46,618

Fair Value Measurements (Assets

Fair Value Measurements (Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis) (Details) - USD ($) $ in Thousands	Apr. 02, 2023	Jan. 01, 2023	Apr. 03, 2022	Jan. 02, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value	$ 15,930	$ 0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	43,834	46,618	$ 49,828	$ 57,996
Fair Value, Recurring [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	13,504	11,083
Investments in US treasury securities	193,963
Foreign exchange derivative assets, net	(332)	(2,142)
Foreign exchange derivative liabilities, net	(794)	(1,549)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value	15,930
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	43,834	46,618
Fair Value, Recurring [Member] | Quoted Prices In Active Markets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	13,504	11,083
Investments in US treasury securities	193,963
Foreign exchange derivative assets, net	0	0
Foreign exchange derivative liabilities, net	0	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	0	0
Fair Value, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0	0
Investments in US treasury securities	0
Foreign exchange derivative assets, net	(332)	(2,142)
Foreign exchange derivative liabilities, net	(794)	(1,549)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	0	0
Fair Value, Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0	0
Investments in US treasury securities	0
Foreign exchange derivative assets, net	0	0
Foreign exchange derivative liabilities, net	0	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value	15,930
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 43,834	$ 46,618

Fair Value Measurements (Reconc

Fair Value Measurements (Reconciliation of Beginning and Ending Level 3 Net Assets) (Details) $ in Thousands	3 Months Ended
	Apr. 02, 2023 USD ($)
Fair Value Disclosures [Abstract]
Balance Beginning of period	$ 0
Amount recognized upon the sale of the Business	15,930
Change in fair value (included within selling, general and administrative expenses)	0
Balance end of period	$ (15,930)

Fair Value Measurements (Reco_2

Fair Value Measurements (Reconciliation of Beginning and Ending Level 3 Net Liabilities) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2023	Apr. 03, 2022
Fair Value Disclosures [Abstract]
Balance beginning of period	$ (46,618)	$ (57,996)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases	0	4,961
Payments	1,424	1,422
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3	0	12,400
Change in fair value (included within selling, general and administrative expenses)	1,360	(693)
Balance end of period	$ (43,834)	$ (49,828)

Contingencies (Details)

Contingencies (Details) $ in Millions	3 Months Ended
	Apr. 02, 2023 USD ($) years	Jan. 01, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Management's estimate of total cost of ultimate disposition | $	$ 13.5	$ 12.2
Number of years over which estimated environmental cost will be paid | years	10

Disposition of Businesses and_2

Disposition of Businesses and Assets, Net (Details) $ in Millions	Mar. 13, 2023 USD ($)
Analytical, Food and Enterprise Services businesses [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Consideration, Receivable at Closing, Deferred Payments Tied to Transfer of the PKI Brand and Related Trademarks	$ 75

Subsequent Events (Details)

Subsequent Events (Details) - Analytical, Food and Enterprise Services businesses [Member] - USD ($) $ in Millions	Mar. 13, 2023	Aug. 01, 2022
Subsequent Event [Line Items]
Disposal Group, Consideration		$ 2,450
Disposal Group, Consideration, Contingent on Exit Valuation	$ 150